We propose the establishment of a SCOR on the Pathogenesis of Scleroderma (SSc) at the University of Tennessee, Memphis. This application brings together a diverse and highly talented group of biomedical scientific investigators with a remarkable history of scientific collaborations and accomplishments in research related to SSc whose attention has now been focused on selected aspects of the biology of the collagenous matrix in SSc which are 1) collagen-induced outgrowth of fibroblast-like cells from cultures of SSc peripheral blood mononuclear cells (PBMC), 2) refractoriness of matrix metalloproteinase (MMP)-1 in SSc lesional fibroblasts to upregulation by cytokines, and 3) collagen-induced platelet aggregation. Project #1 will characterize mechanisms by which type I collagen (CI) induces the outgrowth of FLC from PBMC, a potentially extremely important mechanism by which collagen-producing fibroblasts populate tissues and organs involved in fibrogenesis of SSc. Project #2 addresses the pervasive problem of an inherent resistance of MMP-1 upregulation in lesional SSc fibroblasts by cytokines such as IL-1, TNFalpha, and bFGF. This dysregulation of MMP-1 likely contributes to fibrosis in SSc by leading to decreased removal of collagen in sites where it is being produced. Project #3 will clone and perform functional studies on platelet CI and CIII receptors (R) and will develop blocking peptides that may prove therapeutically useful in halting excessive CI and CIII induced platelet aggregation in SSc patients. An Administrative Core and Molecular Resources Core Laboratory will support the three projects of the SCOR, providing administrative oversight and necessary assistance to each SCOR project. This SCOR will provide a vehicle through which a highly synergistic multidisciplinary approach can be focused on SSc. The spirit of cooperation and collaboration that has been the hallmark over the years of the members of the UT-VAMC Connective Tissue Research Group combined with the commitment of the University of Tennessee, Memphis to this SCOR will assure a successful and expeditious attaining of its goal.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
5P50AR044890-05
Application #
6945457
Study Section
Special Emphasis Panel (ZAR1-AAA-B (M1))
Program Officer
Mancini, Marie
Project Start
2001-08-24
Project End
2008-03-30
Budget Start
2005-08-01
Budget End
2008-03-30
Support Year
5
Fiscal Year
2005
Total Cost
$909,677
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Yin, Zhaohong; Carbone, Laura D; Gotoh, Mari et al. (2010) Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts. Rheumatology (Oxford) 49:2290-7
Postlethwaite, Arnold E; Harris, L Jeff; Raza, Syed H et al. (2010) Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother 11:789-806
Atamas, S P; Luzina, I G; Ingels, J et al. (2010) Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma). Clin Exp Immunol 161:426-35
Chiang, Thomas M; Postlethwaite, Arnold E (2008) Alteration in protein kinase B (AKT) activity in platelets from patients with systemic sclerosis. Thromb Res 122:501-6
Postlethwaite, Arnold E; Wong, Weng Kee; Clements, Philip et al. (2008) A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase di Arthritis Rheum 58:1810-22
Chiang, Thomas M; Postlethwaite, Arnold E (2007) A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim Biophys Acta 1770:1181-6
Du, Haiming; Zawaski, Janice A; Gaber, M Waleed et al. (2007) A recombinant protein and a chemically synthesized peptide containing the active peptides of the platelet collagen receptors inhibit ferric chloride-induced thrombosis in a rat model. Thromb Res 121:419-26
Postlethwaite, Arnold E; Chiang, Thomas M (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574-9
Zhu, Jiaqian; Cole, Flecia; Woo-Rasberry, Virginia et al. (2007) Type I and type III collagen-platelet interaction: inhibition by type specific receptor peptides. Thromb Res 119:111-9
Chiang, Thomas M; Postlethwaite, Arnold E (2006) Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation of lysates of platelets from patients with systemic sclerosis. Biochim Biophys Acta 1760:32-7

Showing the most recent 10 out of 16 publications